Two complementary approaches
At Leksell Social Ventures, our investment strategy is designed to create real, scalable impact through two complementary approaches.
Our investment approach is two-pronged in the sense that it aims to support both unique scientific innovations as well as the necessary implementation of novel methods and therapies. This allows us to work with the leading researchers and entrepreneurs in the life science community - as well as the policy makers and civil servants of the public sector. A way for us to make sure innovation turns into tangible outcomes.
After validating this approach through our initial inception investments we are now scaling this strategy in both strands to further accelerate our impact.
Early-Stage Life Science
We are long-term partners, investing in early and science-driven companies throughout their journey—especially, but not exlusively, in fields of diagnostics, biotech, and data-driven life sciences. Our commitment extends beyond capital, helping promising ventures evolve into transformational leaders in their field, delivering solutions that improve health and wellbeing for all.
Investing in early stage life science companies (from pre-seed stage) offers us the opportunity to drive groundbreaking advancements in healthcare and biotechnology while generating significant long-term value.
The companies we invest in—often founded on cutting-edge research in fields like diagnostics, therapeutics, and data-driven health solutions—are at the forefront of medical innovation, tackling unmet clinical needs and pioneering new modalities for prevention, diagnosis, and treatment.
By providing capital and strategic support, early in their journey, we aim to support in translating promising science from the lab to the clinic, helping startups navigate regulatory pathways, scale operations, and reach transformative milestones. As a long term partner with an evergreen model we aim to invest in our portfolio companies throughout their journey.
Outcomes Models
We invest in initiatives that use rigorous, data-driven outcomes models—enabling us to validate, invest in, and scale what works across the four pillars of society: the private sector, public sector, academia, and the non-profit world. This approach ensures that our capital drives evidence-based solutions with measurable results, wherever the need is greatest.
Investing in outcomes models, such as social impact bonds (SIBs), represents a transformative approach to financing social innovation and public good. Unlike traditional grant funding or service contracts, outcomes models tie financial returns directly to the achievement of measurable social results—
aligning the interests of investors, service providers, and governments. This structure incentivizes evidence-based interventions, rigorous evaluation, and continuous improvement, ensuring that capital is allocated to what truly works.
By shifting risk away from the public sector and toward investors, outcomes models help unlock new funding for high-impact solutions, drive systemic change, and scale proven practices across sectors such as health, education, and employment. Ultimately, they enable a results-driven ecosystem where social value and financial value are created hand-in-hand.